Senior Director, Global Anti-Virals Marketing Team Leader

Pfizer • New York City, NY

6d

About The Position

Pfizer’s industry-leading portfolio of anti- virals - is comprised of Paxlovid and ibuzatrelvir (“ ibuza ”). This new leader will have the opportunity t o concurrently focus on accelerating and reigniting the growth of an in-line brand, while also preparing for launch of a new asset. At launch in the 2021-2022 time - frame , there was tremendous anticipation and unmet need for PAXLOVID as the infection rates swelle d. As the 1 st -to-market oral protease inhibitor for the treatment SARS-CoV-2 , Paxlovid rapidly seized dominant market share leadership, which still holds today . It dwarfed revenue targets and was well on its way to becoming a household name. To date, it’s treated 3M+ patients worldwide. However , the COVID-19 epidemiology evolved following the emergence of the Omicron variant. The ensuing sub-variants were believed to have variable transmission rates, with lower p athogenic ity and virulence, resulting in notably fewer hospitalizations and deaths. This marked the transition of COVID-19 from an epidemic to endemi c. The trend toward fewer and less potent cases was one reason for a sharp drop in Paxlovid prescription volume. T he Paxlovid slowdown was multifactorial. In addition to the epidemiology , the sharp decline in volume is being partially attributed to HCP inertia and patient apathy ( springing from the perception of less severe disease and milder symptoms) , as well as concerns over DDIs and dysgeusia (metallic taste) . A nd, of course, the population at large w as gaining immunity via COVID vaccinations and natural infections, which reduced the addressable patient population. In the aftermath of this raging public health crisis, a deep fatigue set in, particularly amongst HCP s and consumers . All that said, agnostic to the trend in infections, our patient funnel modeling illuminate headroom for growth mid-funnel, specifically in “ patient seeking care” behavior and “HCP treatment rate ”. Ibuza is being developed as a follow-on to Paxlovid, but does not contain ritonavir , whi ch precipitate d DDIs and the dysgeusia . Due to t his favorable product profile , we’ll be evaluating not only the safety and the risk reduction of the composite death/hospital endpoint, but also the impact on symptom alleviation and prevention of post-acute sequelae of COVID. Ibuza’s Ph3 RCT is underway and i s tracking to approval across markets in the 2029-2030 time frame. Interestingly, PAXLOVID has a long runway to LOE, which is slated for 2041. In short, the incoming Senior Director/Global Team Leader for COVID-19 treatmen t will inherit a ~$3B revenue target for 2026, a competitive OpEx budget , and six-to-seven direct reports . In exchange, the new Leader is expected to embrace our franchise purpose to “ensure no eligible high-risk patients are left untreated ” and to champion o u r ambition to further entr ench our market leadership . This role provides an excellent opportunity to shape the commercial potential of both assets. In Global Marketing, we translate science into value for patients.  Our remit is to own the strategic direction across the asset lifecycle, ensure long-term value creation and preservation, and drive brand consistency across markets and efficiencies in execution. This role will report to the Vice President, Global Franchise Lea d for (non-obesity ) IM, AV, and Migraine .

Requirements

• Bachelor’s degree
• 12 + years of commercial experience in the pharmaceutical industry , inclusive of adjacent industries ( eg , consulting, CPG, financial services, academia)
• Expertise in global pharmaceutical/biotech
• Ability to work independently across senior level stakeholders and demonstrates judgement of what needs to be escalated
• Strong team player with demonstrated ability to engage experts from a wide range of functional areas to improve business performance and find a path forward
• Strong strategic thinking, analytical skills, detail and action oriented, creative, flexible, self-motivated
• Proven track record of translating key insights into meaningful strategies and tactics
• Excellent verbal and written communication skills for a wide range of audiences
• Solid understanding of today’s Global and US pharmaceutical environment, including Regulatory, Legal and Compliance
• Is a role model for the Pfizer Values
• Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.

Nice To Haves

• Advanced degree , ideally MBA, MPH, PhD, NP, MD, DO, etc
• Commercial strategy, launch, and lifecycle management experience

Responsibilities

• Recruit, grow, recognize, reward, empower, and promote the top Marketing talent from across Pfizer.
• Shape global commercial strategy and launch strategy, inclusive of brand co- positioning , messaging, and market development , in lock step with ICO, CSI, and US partners.
• Represent Global Commercial voice and point of view on various global governance teams for each asset, as the Lead, Co-Lead or contributor, alongside CSI, Clinical Development, Regulatory, Global Access & Value, and Global Medical Affairs to ensure key opportunities and risks in the clinical development plan meet the target product profile and incorporate commercial insights from inline/launch experiences with Paxlovid .
• Partner with CSI to drive thought leadership on the commercialization plan and lifecycle management priorities to ensure value creation for the mid-to-long term horizon
• Coach, enable, and collaborate with the ibuza Launch Lead and cross-functional partners to ensure launch readiness
• Ensure proactive translation of key competitive intelligence into action; and prepare senior leadership communicati on s
• Make decisions that are in accordance with Company policies and SOPs, Pfizer Values & global regulatory guidelines, and requests consultation when navigating uncertain situations.

Benefits

• participation in Pfizer’s Global Performance Plan with a bonus target of 22.5% of the base salary
• eligibility to participate in our share based long term incentive program
• 401(k) plan with Pfizer Matching Contributions and an additional Pfizer Retirement Savings Contribution
• paid vacation, holiday and personal days
• paid caregiver/parental and medical leave
• health benefits to include medical, prescription drug, dental and vision coverage

What This Job Offers

• Job Type: Full-time
• Career Level: Mid Level
• Number of Employees: 5,001-10,000 employees